drugset
drugset / Trial / NCT04782505

Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy Volunteers

NCT04782505 ↗

Phase 1 Completed 61 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedCrossoverOpen-labelTreatment

Summary

Safety and pharmacokinetics evaluation study according to the dose of camostat mesylate in healthy volunteers

Timeline

Start
2021-03-12
Primary completion
2021-03-16
Completion
2021-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Camostat Small molecule 100 mg Oral
Subject Camostat Small molecule 200 mg Oral
Subject Camostat Small molecule 300 mg Oral

Indications

No indication recorded.